Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_assertion wasGeneratedBy ECO_0000203 NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_assertion wasDerivedFrom befree-20140225 NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_assertion SIO_000772 21406037 NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_assertion evidence source_evidence_literature NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.
- befree-20140225 importedOn "2014-02-25" NP341791.RAzwQKcTD_HaSnR2cFFo7oeJcNZAEx9rv0uvfhKSdR2Os130_provenance.